Professor in the department of Pathology and Molecular Medicine at McMaster University, Past-President of CBMTG, a Director of the Clinical Trials Network and a member of the NIH Consensus Panel for the Diagnosis and Classification of Chronic Graft vs. Host Disease along with several other affiliations. Other activities include board membership on OCREB and panel chair for the CIHR CBT panel. Previous grants with CANVAC, OICR, CIHR, OCRN, and CBCRA and extensive experience in coordinating multi-disciplinary, translational programs.
The outcome of patients diagnosed with multiple myeloma has improved significantly over the past decade. Novel agents used in combination have extended median survival from just 3 years to now 8-10 years. Moreover responses are deeper and more durable. MRD negativity is evolving to be a highly important outcome that may be a surrogate for overall survival.
Review current diagnosis and prognostication for myeloma.